OGXI Share Price

Open 0.46 Change Price %
High 0.49 1 Day 0.02 4.44
Low 0.45 1 Week -0.04 -7.84
Close 0.47 1 Month 0.08 20.51
Volume 216209 1 Year -0.74 -61.16
52 Week High 1.42
52 Week Low 0.33
OGXI Important Levels
Resistance 2 0.51
Resistance 1 0.49
Pivot 0.47
Support 1 0.45
Support 2 0.43
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)

OGXI Technical Analysis 2
As on 5th Dec 2016 OGXI Share Price closed @ 0.47 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.73 & Buy for SHORT-TERM with Stoploss of 0.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
OGXI Target for December
1st Target up-side 0.61
2nd Target up-side 0.71
3rd Target up-side 0.81
1st Target down-side 0.31
2nd Target down-side 0.21
3rd Target down-side 0.11
OGXI Other Details
Segment EQ
Market Capital 178379728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncogenex.com
OGXI Address
OGXI
1522- 217th Place SE
Suite 100
Bothell, WA 98021
United States
Phone: 425-686-1500
Interactive Technical Analysis Chart OncoGenex Pharmaceuticals Inc. ( OGXI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on OncoGenex Pharmaceuticals Inc.
OGXI Business Profile
OncoGenex Pharmaceuticals, Inc. (OncoGenex) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has four product candidates in its pipeline: custirsen, OGX-427, OGX-225 and CSP-9222. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company�s product candidates custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells, and are over-produced in response to a variety of cancer treatments. Product candidate CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer and demonstrate activation of programmed cell death in pre-clinical models.